Previous 10 | Next 10 |
Dicerna Pharmaceuticals (DRNA): Q1 GAAP EPS of -$0.39 misses by $0.02.Revenue of $47.6M (+39.9% Y/Y) misses by $1.46M.Press Release For further details see: Dicerna Pharmaceuticals EPS misses by $0.02, misses on revenue
– Announced Sale of OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million; Extends Cash Runway Into 2024 – – Earned $25 Million Milestone Payment in Connection With Roche’s Initiation of GalXC™ RNAi Candidate RG...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2021 financial results aft...
Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $30.19, eclipsing its 52-week high. Approximately 106,000 shares have changed hands today, as compared to an average 30-day volume of 761,000 shares. Dicerna Pharmaceuticals Inc is a biotechnology company involved in th...
Royalty Pharma (RPRX) has acquired the royalty interest of Oxlumo™ (lumasiran) from Dicerna Pharmaceuticals (DRNA) for a total consideration of up to $240M.As part of the agreement, Dicerna is entitled to receive $180M as an upfront cash payment in addition to contingent sale...
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq...
– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) to...
Announcing new preclinical data, Dicerna Pharmaceuticals ([[DRNA]] +3.0%) said that its GalXC-Plus™ RNAi technology had the potential to deliver a ‘deep and sustained’ messenger RNA (mRNA) knockdown against specific gene targets in the Central Nervous System.Rather than t...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technolog...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...